2026-07-15
NordicAST Project Grants
Published at 2019.02.01
We have become aware of two errors in the Breakpoint tables which concern breakpoints/ECOFFS.
In the Norwegian version, the note on enterococci for trimethoprim and trimethoprim-sulfamethoxazole contains an error. It should read:
“Effekten av trimetoprim og trimetoprim-sulfametoxazole er usikker hos enterokokker og det er ikke mulig å forutsi klinisk effekt. ECOFF som er benyttet for å kategorisere isolatene som villtype eller ikke-villtype for både E. facealis og E. faecium er 1 mg/L med en korresponderende sonediameter ECOFF på 21 mm for trimetoprim og 23 mm for trimetoprim-sulfametoxazole.”
In all 3 versions, in the Enterobacterales worksheet, the note on Yersinia enterocolitica should refer to doxycycline, not tigecycline:
“Tetracycline has been used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections (tetracycline MIC ≤4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 µg disk is ≥19 mm.”
2026-07-15
NordicAST Project Grants
2026-07-15
Publication of Updated EUCAST Clinical Breakpoint tables, version 16.1.
2026-05-29
NordicAST workshop 2026 - Presentations now available to view online